• Publications
  • Influence
Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates
ObjectiveTo evaluate the immunogenicity and efficacy of an inactivated dual-subtype feline immunodeficiency virus (FIV) vaccine. DesignSpecific-pathogen-free cats were immunized with dual-subtypeExpand
  • 66
  • 4
Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.
IntroductionFeline immunodeficiency virus (FIV) infection is a natural infection of domestic felid populations which results in a chronic and progressive acquired immunodeficiency syndrome [1–3]. FIVExpand
  • 61
  • 4
Immunohistochemical and in situ hybridization studies of gonadotropin releasing hormone (GnRH) and its receptor in rat digestive tract.
GnRH(LH-RH) is first discovered in the hypothalamus and found to have a role in regulation of reproduction. With the study on it deepening, GnRH was demonnstrated that it also exists in a number ofExpand
  • 24
  • 4
Superinfection of cats with feline immunodeficiency virus subtypes A and B.
The ability of feline immunodeficiency virus (FIV) isolates from subtypes A and B to superinfect cats and cell cultures was tested. Three specific pathogen-free (SPF) cats were first inoculated withExpand
  • 39
  • 3
Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.
More than 90% of cats immunized with inactivated whole infected-cell or cell-free feline immunodeficiency virus (FIV) vaccines were protected against intraperitoneal infection with 10 50% animalExpand
  • 108
  • 2
  • PDF
FIV vaccine development and its importance to veterinary and human medicine: a review
Abstract Feline immunodeficiency virus (FIV) is a natural infection of domestic cats that results in acquired immunodeficiency syndrome resembling human immunodeficiency virus (HIV) infection inExpand
  • 99
  • 2
Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against a heterologous subtype B FIV isolate
Vaccine trials were undertaken to determine whether the Fel-O-Vax® FIV, a commercial dual-subtype (subtypes A and D) feline immunodeficiency virus (FIV) vaccine, is effective against a subtype B FIVExpand
  • 54
  • 2
Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
Vaccine-induced T cell responses to FIV were assessed by measuring FIV-specific cytokine and cytotoxic-effector molecule production. A total of 22 cats at 10-12 weeks of age received eitherExpand
  • 28
  • 2
Efficacy evaluation of prime–boost protocol: canarypoxvirus‐based feline immunodeficiency virus (FIV) vaccine and inactivated FIV‐infected cell vaccine against heterologous FIV challenge in cats
Objective:To evaluate the immunogenicity and prophylactic efficacy of immunization schemes employing a recombinant canarypoxvirus (‘ALVAC’)-based feline immunodeficiency virus (FIV) vaccine alone orExpand
  • 52
  • 1
HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection
Background:Based on previous analysis of feline immunodeficiency virus (FIV)-specific cross-reactive antibodies to HIV-1 p24, cats vaccinated with HIV-1 p24 were evaluated for cross-reactive immunityExpand
  • 22
  • 1